New and Emerging Therapies for Dyslipidemia
Atherosclerotic cardiovascular disease (ASCVD) continues to represent a growing global health challenge. Despite guideline-recommended treatment of ASCVD risk, including antihypertensive, high-intensity statin therapy, and antiaggregant agents, high-risk patients, especially those with established ASCVD and patients with type 2 diabetes, continue to experience cardiovascular events. Recent years have brought significant developments in lipid and atherosclerosis research. Several lipid drugs owe their existence, in part, to human genetic evidence. Here, the authors briefly review the mechanisms, the effect on lipid parameters, and safety profiles of some of the most promising new lipid-lowering approaches that will be soon available in our daily clinical practice.
Source: Endocrinology and Metabolism Clinics of North America - Category: Endocrinology Authors: Alberto Zambon, Maurizio Averna, Laura D ’Erasmo, Marcello Arca, Alberico Catapano Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Heart | Statin Therapy